PharmaWeek
Wed., December 03, 2008 |  PharmaWeek.com | Archives | Advertising | Your Account | CHI Conferences |  Subscribe |

Industry Trends

U.S. Generic Drug Market Outlook to 2012
By Mark P. Mathieu

Since drugs with $50 billion on 2007 U.S. sales are scheduled to lose patent/exclusivity protection in 2008 – 2010, the three-year period presents formidable obstacles for the pharmaceutical industry. Marketing exclusivity … Read more

Sales Contacts
For advertising information contact: 

Tom Loughran
Regional Sales Manager, Advertising Sales -Midwest, South Eastern US, Europe
781-972-5482

Contact the Editor
Alissa PohPharmaWeek welcomes your feedback. Please contact Alissa Poh for editorial inquiries.

Link to Us! 
You are welcome to link to articles on our website. Contact Catherine Varmazis for details.

e-Prints & Reprints 
To post a full article from PharmaWeek or Bio-IT World on your website (not just a link), or for paper reprints, please contact:
Ashley Zander
The YGS Group
717-399-1900 ext.125

Dear Colleague,
Welcome to this week's eNewsletter covering breaking R&D news, business insights, and a chat with Dana-Farber pediatric oncologist Alan d'Andrea about his business venture, The DNA Repair Company.
 

 
  
 
FEATURE  
 

PharmaSpeak: Alan d’Andrea – The DNA Repair Company
By Kevin Davies

Pediatric oncologist Alan d’Andrea has enjoyed a distinguished academic career over the past two decades. As a postdoc at the Whitehead Institute in the late 80s, he almost single-handedly cloned the erythropoietin receptor. At the Dana Farber Cancer Institute, his interests pivoted toward Fanconi anemia (FA), a rare genetic cancer disorder where patients are prone to solid tumors, leukemias, and bone marrow failure. d’Andrea’s group has helped define some of the disease’s 13 known mutated genes and the underlying biochemical pathways. Now, as co-founder of The DNA Repair Company (DNAR), d’Andrea is hoping that his insights into the mechanisms of DNA repair’s six major pathways will help pharma identify patient responders and improve drug safety.


PharmaWeek recently caught up with d’Andrea in his Dana-Farber digs to learn more about the commercial prospects of analyzing DNA repair.
More

 
 
BREAKING R&D NEWS
 

Absence of Evidence
The Economist [Nov 27] A study published this week in PLoS Medicine, an online journal, confirms what many have suspected and what previous studies have hinted at: drug companies try to spin the results of clinical trials. More

Genes Can Predict Whether Lymphoma Therapy Will Work
Bloomberg [Nov 26] A gene-based test can predict how patients will respond to treatment for non-Hodgkin’s lymphoma. More

Patient-Led Drug Trials Defy Medical Establishment
Associated Press [Nov 26] Dozens of ALS patients are testing treatments on their own without waiting on the slow pace of medical research. They are part of an emerging group of patients willing to share intimate health details on the Web in hopes of making their own medical discoveries. More

New Arena for Testing of Drugs: Real World
New York Times [Nov 24] A group of advocates, including medical researchers, medical societies and insurers, is lobbying Congress to pay for an Institute for Comparative Effectiveness Research that would assess treatments and identify gaps in evidence. When there are gaps, the institute would initiate what are being called “real world,” or “pragmatic,” clinical research trials to gather the evidence. More

Genentech's Avastin Meets Breast Cancer Study Goal
Forbes [Nov 24] Genentech’s key revenue driver, the blockbuster drug Avastin, improved the survival time for breast cancer patients in a late-stage study, putting the drug closer to full regulatory approval to treat the condition. More

NCCN Receives Grant to Study Cetuximab in Bladder Cancer
MarketWatch [Nov 24] The National Comprehensive Cancer Network has received funding from BMS and ImClone for a multi-institutional investigation into the use of cetuximab for bladder cancer, the fifth most common type in the US. More

 
 
BUSINESS INSIGHTS 
 

Merck's Former Seattle Chief Will Now Run Merck Boston
Bio-IT World [Dec 2] Just a few weeks after closing its Seattle facility, Merck announced on Tuesday that Rupert Vessey, the former Seattle site head, will become head of basic research at Merck Research Laboratories in Boston, replacing Lex Van der Ploeg, who is retiring. More

The Case for Pfizer
CNN Money [Dec 1] The healthcare giant faces a steep patent cliff - but it has the cash to bridge it. More

Health-Care Stocks: The Obama Effect
BusinessWeek [Dec 1] S&P equity analysts examine the ramifications for the industry of potential policy moves by the new administration. More

Big Pharma Faces a Crackdown in Europe
Time [Nov 28] The pharmaceutical industry is one of the few sectors around that appears to be weathering these difficult times with relative ease. Last Friday, the European Commission suggested why that might be: it claims Big Pharma systematically rigged the market to squeeze out copycat medicines. More

EU Has “Declared War on Pharma,” Expert Warns
PharmaTimes [Dec 1] European Commission investigators will carry out more dawn raids on pharmaceutical manufacturers, and both originator and generics companies will need to review the way they do business to ensure they do not become the subject of antitrust litigation, leading experts have warned. More

Teva Grabs Billions Gambling on Copies of Brand Drugs
Bloomberg [Dec 1] Israel’s largest drug company turned itself into the world’s biggest maker of generic medicines through a high-risk strategy of flouting drug patents. Its next target may be Lilly’s Evista, for osteoporosis. More

Viehbacher, Passed Over at Glaxo, Takes Sanofi Reins
Bloomberg [Dec 1] Chris Viehbacher is now top man at Sanofi-Aventis, taking over from Gerard le Fur, who was ousted in September after the company faced issues with both Acomplia and Plavix. More

Indonesia Toughens Up on Drug Companies
Straits Times [Nov 24] Foreign drug companies can quit Indonesia if they do not like new rules requiring them to have local production facilities, according to Health Minister Siti Fadilah Supari. The rules, which have drawn protests from the US Chamber of Commerce, affect 13 international pharma companies, including Lilly, Roche, and AstraZeneca. More

 
 
LAST WEEK'S TOP STORY
 

PharmaSpeak: James Greenwood, The Biotechnology Industry Organization (BIO)

PharmaWeek [Nov 19] Jim Greenwood, BIO’s president and CEO, is a familiar face in many Washington, D.C. circles, having represented Pennsylvania’s Eighth District in the US House of Representatives for 12 years (1993-2005). In January 2005, he took over the leadership reins at BIO, which provides advocacy, business development, and communications services for more than 1,200 members across the globe.

PharmaWeek recently secured approximately 20 minutes of Greenwood’s time for a Q&A on the upcoming change in administration, and its impact on pharma/industry. More

For More Recent Articles >>

 

LIFE SCIENCE JOBS

Lilly Singapore Centre for Drug Discovery - Bioinformatics Manager- For more information click here 

Lilly Singapore Centre for Drug Discovery - Senior Statistical Geneticist- For more information click here  

Monsanto Scientific Software Design Opportunities
Monsanto has several exciting, cutting-edge opportunities in its software design group, Technology Pipeline Solutions (TPS), which require a scientific background and an interest in software development. Join a leader in biotechnology agriculture by working to design customized software solutions for our research and development groups. Please visit www.monsanto.com and search for the following four positions: Emerging Strategies Lead, Strategic Scientist, Engagement Manager and Scientific Business Analyst.  Monsanto values diversity and is an equal opportunity employer. M/F/D/V

Director, Center For Information Technology (CIT) - National Institutes of Health  (NIH), Department of Health and Human Service
Located in Bethesda, MD. This position requires:
• High-level vision, leadership, management, and modernization of CIT programs and services.
• Strategic direction and policy development for CIT long-term operations and objectives.
• Serve as a key IT advisor to the NIH Chief Information Officer.
A TOP SECRET security clearance will be required.  More job detail is found at: 
 http://www.jobs.nih.gov under the Executive Jobs section.Or contact Ms.Winnie Garner at seniorre@od.nih.gov.  Applications must be received ELECTRONICALLY by (11:59 p.m.), December 17, 2008.  DHHS and NIH are Equal Opportunity Employers

More Life Science Jobs ~ Add a Job Listing

 

FEATURED EVENTS 

The 4th Annual World Healthcare Innovation and Technology Congress - December 8 – 10, 2008 | Washington, DC

The Association for Laboratory Automation (ALA) presents LabAutomation2009, January 24-28, in Palm Springs, CA. 

Electronic Laboratory Notebooks - 28th - 29th, January 2009, Copthorne Tara Hotel, London, United Kingdom

TEPR+ 2009 - Feb 1-5, 2009 | Palm Springs, CA

The World Health Care Congress 2nd Annual Leadership Summit on Consumer Connectivity & Web Empowerment | February 23 – 24, 2009-Carlsbad, CA 

7th Annual Bio-IT World Conference - April 2009

Storage for Science Seminar Series-See Schedule Here

Barnett Educational Services

Cambridge Healthtech Events

To have your event featured here, contact Lynn Cloonan for more information. 
 Email to a Friend 

PharmaMatters

Wyeth Ranked #1 Innovator in Pharmaceutical Industry  

Dec 2, 2008 | The Patent Board recently published their Pharmaceutical Patent Scorecard, a quarterly snap-shot that ranks pharmaceutical companies’ patent activity over the last 13 weeks. Each company’s portfolio was measured on technical strength, quantity, science and research strength, as well as the speed at which patents became assets. In this most recent scorecard, Wyeth holds its position as top dog, with BMS on its heels, and J&J pushing Pfizer out of third place. Celgene also managed to move into the top 10 for the first time. Read More

EXCLUSIVE WEBCAST

Life Science Webcasts from Bio-IT World and Cambridge Healthtech Media Group

Life Science Webcasts

NEW!
Exploring Next-Generation Sequencing
Bio-IT World Editor-in-Chief Kevin Davies interview BGI's Laurie Goodman on the sequencing of the first Asian genome. View the webcast.

Drug Discovery, Development and Commercialization: Evolving Challenges and Opportunities
Joshua Boger, PhD, president and CEO, Vertex Pharmaceuticals Inc., delivers his keynote at the 2008 Bio-IT World Conference & Expo in Boston, April 2008.
View the Webcast Now.

Personalized Genetics: Advancements and Driving Change
Linda Avey, co-founder of 23andMe, delivers her keynote at the 2008 Bio-IT World Conference & Expo in Boston, April 30, 2008.
View the Webcast Now.

The Future of Personal Genomics
A distinguished panel of personal genomics experts discuss the future of personal genomics at the 2008 Bio-IT World Conference & Expo in Boston, April 30, 2008.  They include Dietrich Stephan (co-founder, Navigenics); George Church (Harvard Medical School);
Jeff Drazen (editor-in-chief, New England Journal Medicine); Fred Ledley (Bentley College); John Halamka (CIO, Harvard Medical School); and Linda Avey (23andMe). Bio-IT World Editor-in-Chief Kevin Davies moderates the discussion.
View the Webcast Now

Bio-IT World's 2009
Best Pract
ices Awards

Entry forms are now available for Bio-IT World’s 2009 Best Practices Awards program. This has long been one of our most successful programs. Last year, there were 56 entries and we awarded 15 prizes at a gala dinner held during the Bio-IT World Conference & Expo in the spring. This year we are hoping to expand those numbers. 
The program is intended to spotlight companies whose use of innovative technologies is making a positive difference in biomedical R&D and drug discovery and development.
Bio-IT World is also making available a free compendium of Best Practice entries from 2008 to help ensure the lessons learned are widely spread. The compendium can be downloaded here.

Meanwhile, get started on this year’s entries. There are nine categories, shown below. The deadline is mid-January 2009. Full details of the entry process and the entry form are available by clicking here.

2009 Best Practices Categories:
*Basic Research & Biological Research
*Drug Discovery & Development
*Clinical Trials & Research
*Translational Medicine
*Personalized Medicine
*IT & Informatics
*Knowledge Management
*Health-IT
*Manufacturing & Bioprocessing

All of the entries will be reviewed and ranked by a panel of experts assembled by Bio-IT World editors. Winners will be announced at a dinner ceremony held in Boston in April 2009 in conjunction with the Bio-IT World Conference & Expo. If you have questions, write to john_russell@bio-itworld.com 
Insight Pharma Reports

Stem Cells Come of Age

Considers applications of stem cell science in drug development & regenerative medicine and examines sources of funding, regulatory hurdles, the commercial outlook, and much more. More Information

Featured Content

High-Performance Computing in Life Science & Education, underwritten by SGI and Intel 

The varied collection of Bio-IT World articles and insights assembled in this BriefingON examine key trends in HPC infrastructure and how researchers are putting their best computational resources to use. Provided here are stories and lessons around the effective use of high performance computing in life science. Download the BriefingON. 

10 Secrets to Recession-Proof Your Business
Sponsored by Coupa

Read this white paper to discover 10 strategies smart companies deploy to recession-proof their business.
Leaders generally face hard choices on how to mange a company during an economic downturn and
behave in one of three ways:
• “The ostrich” - Preserve the status quo/hope for the best
• “The bull in the china shop” - Blindly cut expenses across the board
• “The fox” - Use the downturn to make your business more effective and position it for future growth.
Learn how to behave “like a fox” and use a recession as a means to pounce on emerging trends.
Download This Complimentary Paper.

Next Generation Sequencing  Learn how labs can maximize the value they receive from their next generation sequencing instruments:
sponsored by Genologics

How can labs generate value from their next generation sequencing instruments
What are the data management challenges for labs conducting next generation sequencing
What do genomics labs need to look for when evaluating lab and data management systems
How are different labs using a lab and data management system to address their data management challenges
Download Now 

To have your white paper featured here, contact Lynn Cloonan for more information.


Cambridge
                                Healthtech InstitutePublished by Cambridge Healthtech Institute (CHI). Copyright © 2008, all rights reserved. No material may be reproduced electronically or in print without written permission from CHI, 250 First Ave., Needham, MA 02494-2814. For reprints and/or copyright permission, please contact The YGS Group, 1808 Colonial Village Lane, Lancaster, PA; 17601 717-399-1900 ext.125, or email: Ashley.Zander@theYGSgroup.com